Richard L. Dunbar

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Preventive Cardiovascular Medicine Clinic, University of Pennsylvania School of Medicine
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Member, Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine
Department: Medicine

Contact information
Perelman School of Medicine at the University of Pennsylvania
3600 Spruce Street
0846 Maloney Building
Philadelphia, PA 19104-2699
Office: Clinic (215) 615-8659
Lab: (215) 315-3378
Education:
B.A. (Environmental Sciences)
University of Virginia, Charlottesville, VA, 1992.
M.D. (Medicine)
Medical College of Virginia, Richmond, VA, 1997.
M.S. (Translational Research)
University of Pennsylvania School of Medicine, Philadelphia, PA, 2008.
Permanent link
 

Description of Research Expertise

Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of nicotinic acid (niacin). He has developed sophisticated objective techniques to quantify the physical stigmata of flushing from niacin. He combines these techniques with laboratory pharmacodynamic studies to elucidate the integrated physiology of the response to niacin.

Description of Itmat Expertise

Dr. Dunbar studies the dyslipidemia of metabolic syndrome and type 2 diabetes and is involved in mechanistic clinical research related to high-density lipoprotein, triglycerides, and post-prandial lipidemia. He has a particular interest in understanding the mechanism of action and mechanism of adverse effects of niacin. Dr. Dunbar can accommodate a limited number of research observerships.

Selected Publications

Tuteja S, Duffy D, Dunbar RL, Movva R, Gadi R, Bloedon LT, Cuchel M : Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia. Pharmacotherapy 34(3): 213–314, March 2014.

Donovan J, Dunbar R, Biernat L, Logan D, Curtis M, Mancini M, Jirousek M: Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Demonstrates Reductions in Postprandial Triglycerides [Poster Presentation] JACC March 2014 Notes: 63rd Annual Scientific Session of the American College of Cardiology, Washington, DC, March 2014.

Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH: A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). Clinical Therapeutics 35(9): 1400-1411, September 2013.

Dunbar RL, Cuchel M, Millar JS, Baer A, Poria R, Freifelder RH, Pryma DA, Billheimer JJ, Rader DJ: Niacin Does Not Accelerate Reverse Cholesterol Transport in Man [Poster Presentation] ATVB April 2013 Notes: Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, Lake Buena Vista, FL, April 2013.

Tuteja S, Dunbar R, Qu L, Li M, Mucksavage M, DerOhannessian S, Reilly M, Rader DJ: Perilipin 1 (PLIN1) genotype and not GPR109A associated with free fatty acid rebound following niacin administration [Poster Presentation] ATVB April 2013 Notes: Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, Lake Buena Vista, FL, April 2013.

deGoma,EM* and Dunbar, RL*, Jacoby, D, and French, B: Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations. Atherosclerosis 227(1): 172-7, March 2013 Notes: *Co-first authors, equal contribution.

Maki KC, Orloff D, Nicholls S, Dunbar R, Roth E, Curcio DL, Johnson J, Kling DF, Davidson MH: A Highly Bioavailable Omega-3 Free-Fatty Acid Reduces Non-High Density Lipoprotein Cholesterol in High-Risk Patients Treated with a Statin and Residual Hypertriglyceridemia (ESPRIT Trial) [Poster Presentation] JACC 61(10): E1468, March 2013 Notes: 62nd Annual Scientific Session of the American College of Cardiology, San Fransisco, CA, March 2013.

deGoma,EM, Davis, MD, Dunbar, RL, Mohler, ER, III, Greenland, P, and French, B: Discordance between non-HDL-cholesterol and LDL-particle measurements: Results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis March 2013.

Rader DJ, Dunbar RL, Maki KC, Jacobson TA, Kling D, Davidson MH : Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients with Severe Hypertriglyceridemia and Changes Correlate with Increases in LDL-C: A Sub-analysis of the EVOLVE trial [Poster Presentation] Circulation 126(Supplement 21): A19030, November 2012 Notes: American Heart Association Scientific Sessions 2012, Los Angeles, CA, November, 2012.

Qamar A, Usman H, Reilly M, Dunbar R, Rader D: Niacin Reverses Increased Plasma PCSK9 Induced by Statin and Fibrate Therapy: A Novel Mechanism for Further LDL Reduction [Poster Presentation] Circulation 126(Supplement 21): A13757, November 2012 Notes: American Heart Association Scientific Sessions 2012, Los Angeles, CA, November, 2012.

back to top
Last updated: 05/23/2014
The Trustees of the University of Pennsylvania